SCHEMBL9963472

SCHEMBL9963472

CN1CCN(C(=O)CNC(=S)Nc2cc(NC(=S)NCC(=O)N3CCN(C)CC3)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
STAT3 P40763 1/20 0.47
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MYC P01106 1/20 0.43
MAX P61244 1/20 0.43
EPHX2 P34913 4/20 0.43
KDM1A O60341 2/20 0.42
MAOB P27338 2/20 0.42
MAOA P21397 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GPR35 Q9HC97 1/20 0.40
CCR3 P51677 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963475 0.78 ALDH1A1 (0.48) LMNAHTTSMN1; SMN2L3MBTL1MEN1
SCHEMBL9963478 0.74 LMNA (0.46) LMNAHTTSMN1; SMN2L3MBTL1MEN1
SCHEMBL9963608 0.73 L3MBTL1 (0.49) SMN1; SMN2L3MBTL1MEN1KMT2AKDM4E
SCHEMBL9963505 0.71 ALDH1A1 (0.52) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL5205367 0.70 LMNA (0.66) LMNAHTTSMN1; SMN2EPHX2L3MBTL1
SCHEMBL2161427 0.69 MYC (0.61) LMNAHTTSMN1; SMN2MYCMAX
SCHEMBL25413554 0.68 KMT2A (0.54) LMNASTAT3SMN1; SMN2EPHX2MAOB
SCHEMBL24742689 0.68 MYC (0.53) LMNAHTTSMN1; SMN2MYCMAX
SCHEMBL18330292 0.67 MAPT (0.63) LMNAHTTSMN1; SMN2MYCMAX
SCHEMBL30413682 0.66 MYC (0.55) LMNAHTTSMN1; SMN2MYCMAX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032583-B1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 EP disclosed
US-8203001-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-19 US disclosed
US-8203001-B2 Chemical compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-19 US disclosed
US-20090258857-A1 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 US disclosed
US-20090258857-A1 CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 US disclosed
WO-2007144370-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258857-A1 CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 LMNA 157/4885STAT3 2402/4885HTT 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.